L-asparaginase (NSC-109229) plus azaserine (NSC-742) in acute lymphatic leukemia.
D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001377:Azaserine / Q000009:adverse effects / Q000627:therapeutic use*; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004926:Escherichia coli / Q000201:enzymology; D006801:Humans; D007019:Hypoproteinemia / Q000139:chemically induced; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D010195:Pancreatitis / Q000139:chemically induced; D012075:Remission, Spontaneous; D013237:Stereoisomerism; D013921:Thrombocytopenia / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D004338:Drug Combinations; D001377:Azaserine; D001215:Asparaginase